On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.

The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

A source of the parasites has not yet been found. The Food and Drug Administration first reported the outbreak on Aug. 7 and the patient count has steadily… A Codex committee has made progress ...

The target of the strike in Lebanon was the group’s leader, Hassan Nasrallah, according to Israeli and American officials. The attack came shortly after the Israeli prime minister gave a defiant ...

Israel will continue to discuss ceasefire proposals for Lebanon in the days ahead, Prime Minister Benjamin Netanyahu said on Friday, as Washington warned that further escalation would only make it ...